Covid-19 roundup: Cure­Vac push­es ahead for vac­cine au­tho­riza­tion de­spite fail­ing to hit 50% ef­fi­ca­cy thresh­old

All mR­NA vac­cines are not cre­at­ed equal. And Ger­many-based Cure­Vac found out the hard way on Wednes­day as its piv­otal tri­al showed its vac­cine is 48% ef­fec­tive against Covid-19 across all age groups stud­ied.

While reg­u­la­tors have set the ef­fi­ca­cy bar at 50% for new Covid-19 vac­cines, Cure­Vac CEO Franz-Wern­er Haas made clear on Wednes­day that he still in­tends to still seek li­cen­sure for the vac­cine, par­tic­u­lar­ly in the EU and for cer­tain age groups that per­formed bet­ter in the tri­al than the over­all re­sult.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER